IDEXX Laboratories (TICKER: IDXX) Benchmark And Performance Data

there are 12 of samples in the benchmark for IDEXX Laboratories in year 2022 in 2022. The total inventory for IDEXX Laboratories was $269,030,000.00 in 2021. The total inventory for IDEXX Laboratories was $209,873,000.00 in 2020. The total inventory for IDEXX Laboratories was $195,019,000.00 in 2019. The total inventory for IDEXX Laboratories was $188,833,000.00 in 2015. The total inventory for IDEXX Laboratories was $173,303,000.00 in 2018. The total inventory for IDEXX Laboratories was $164,318,000.00 in 2017. The total inventory for IDEXX Laboratories was $160,342,000.00 in 2014. The total inventory for IDEXX Laboratories was $158,034,000.00 in 2016. The total inventory for IDEXX Laboratories was $140,946,000.00 in 2012. The total inventory for IDEXX Laboratories was $133,427,000.00 in 2013. The sales, general, and administrative (SGA) for IDEXX Laboratories was $796,395,000.00 in 2021. The sales, general, and administrative (SGA) for IDEXX Laboratories was $735,267,000.00 in 2020. The sales, general, and administrative (SGA) for IDEXX Laboratories was $679,510,000.00 in 2019. The sales, general, and administrative (SGA) for IDEXX Laboratories was $632,344,000.00 in 2018. The sales, general, and administrative (SGA) for IDEXX Laboratories was $575,172,000.00 in 2017. The sales, general, and administrative (SGA) for IDEXX Laboratories was $524,075,000.00 in 2016. The sales, general, and administrative (SGA) for IDEXX Laboratories was $482,465,000.00 in 2015. The sales, general, and administrative (SGA) for IDEXX Laboratories was $457,598,000.00 in 2014. The sales, general, and administrative (SGA) for IDEXX Laboratories was $401,353,000.00 in 2013. The sales, general, and administrative (SGA) for IDEXX Laboratories was $354,571,000.00 in 2012. The sales, general, and administrative (SGA) for IDEXX Laboratories was $$851,000,000 in 2022. The revenue volatility for IDEXX Laboratories was 16.08% in 2022. The market capitalization for IDEXX Laboratories was $55,680,694,520.00 in 2014. The market capitalization for IDEXX Laboratories was $53,741,747,250.00 in 2012. The market capitalization for IDEXX Laboratories was $52,786,872,000.00 in 2013. The market capitalization for IDEXX Laboratories was $46,042,757,840.00 in 2015. The market capitalization for IDEXX Laboratories was $41,715,223,800.00 in 2020. The market capitalization for IDEXX Laboratories was $41,508,140,240.00 in 2019. The market capitalization for IDEXX Laboratories was $36,298,835,646.00 in 2021. The market capitalization for IDEXX Laboratories was $33,786,005,777.00 in 2018. The market capitalization for IDEXX Laboratories was $29,260,702,440.00 in 2016. The market capitalization for IDEXX Laboratories was $27,039,771,000.00 in 2017. The market capitalization for IDEXX Laboratories was $$43,204,000,000 in 2022. The gross revenue for IDEXX Laboratories was $3,215,360,000.00 in 2021. The gross revenue for IDEXX Laboratories was $2,706,655,000.00 in 2020. The gross revenue for IDEXX Laboratories was $2,406,908,000.00 in 2019. The gross revenue for IDEXX Laboratories was $2,213,242,000.00 in 2018. The gross revenue for IDEXX Laboratories was $1,969,058,000.00 in 2017. The gross revenue for IDEXX Laboratories was $1,775,423,000.00 in 2016. The gross revenue for IDEXX Laboratories was $1,601,892,000.00 in 2015. The gross revenue for IDEXX Laboratories was $1,485,807,000.00 in 2014. The gross revenue for IDEXX Laboratories was $1,377,058,000.00 in 2013. The gross revenue for IDEXX Laboratories was $1,293,338,000.00 in 2012. The gross revenue for IDEXX Laboratories was $$3,367,000,000 in 2022. The gross margin for IDEXX Laboratories was $26.69% in 2022. The days sales outstanding for IDEXX Laboratories was 42 days in 2022. The days payable outstanding for IDEXX Laboratories was 30 days in 2022. The days of inventory for IDEXX Laboratories was $85 in 2022. The cost of goods sold (COGS) for IDEXX Laboratories was 40.48% in 2022. The cost of goods sold (COGS) for IDEXX Laboratories was $971,700,000.00 in 2018. The cost of goods sold (COGS) for IDEXX Laboratories was $871,676,000.00 in 2017. The cost of goods sold (COGS) for IDEXX Laboratories was $799,987,000.00 in 2016. The cost of goods sold (COGS) for IDEXX Laboratories was $711,622,000.00 in 2015. The cost of goods sold (COGS) for IDEXX Laboratories was $669,691,000.00 in 2014. The cost of goods sold (COGS) for IDEXX Laboratories was $620,940,000.00 in 2013. The cost of goods sold (COGS) for IDEXX Laboratories was $594,190,000.00 in 2012. The cost of goods sold (COGS) for IDEXX Laboratories was $1,325,928,000.00 in 2021. The cost of goods sold (COGS) for IDEXX Laboratories was $1,135,615,000.00 in 2020. The cost of goods sold (COGS) for IDEXX Laboratories was $1,041,359,000.00 in 2019. The cost of goods sold (COGS) for IDEXX Laboratories was $$1,363,000,000 in 2022. The cash to cash cycle time for IDEXX Laboratories was 97 in 2022. The annual percentage growth rate of IDEXX Laboratories was -0.05% in 2022. IDEXX Laboratories in its benchmark peer group, had rank 8 for cash to cash cycle time in 2022. IDEXX Laboratories in its benchmark peer group, had rank 7 for sales growth in 2022. IDEXX Laboratories in its benchmark peer group, had rank 6 days for days of inventory in 2022. IDEXX Laboratories in its benchmark peer group, had rank 4 for cost of goods sold as a percent of revenue in 2022. IDEXX Laboratories in its benchmark peer group, had rank 2 days for days sales outstanding in 2022. IDEXX Laboratories in its benchmark peer group, had rank 10 for gross revenue in 2022. IDEXX Laboratories headquarters region is East. IDEXX Laboratories has ticker symbol IDXX. IDEXX Laboratories has the following profile: IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.. IDEXX Laboratories has primary indstury Diagnostics & Research. IDEXX Laboratories had a $$2,341,000,000 gap between actual performance and next performance rank for gross revenue in competitive benchmarking in 2022. IDEXX Laboratories had Revvity, Inc., and Danaher, and Thermo Fisher Scientific Inc., and Laboratory Corp. of America, and IQVIA Holdings, and Illumina, and Charles River Laboratories International, and Quest Diagnostics, and Agilent Technologies, and Mettler-Toledo International, and IDEXX Laboratories, and Waters benchmark peer companies for its SIC code in 2022. IDEXX Laboratories had 40 days gap between actual performance and next performance rank for cash to cash in competitive benchmarking in 2022. IDEXX Laboratories had 39 days gap between actual performance and next performance rank for days of inventory in competitive benchmarking in 2022. IDEXX Laboratories had 2.22% gap between actual performance and next performance rank for sales volatility in competitive benchmarking in 2022. IDEXX Laboratories had 111.00% gap between actual performance and next performance rank for cost of goods sold as a percent of revenue in competitive benchmarking in 2022. IDEXX Laboratories had 10,780 number of employees in 2022. IDEXX Laboratories had 1.93% gap between actual performance and next performance rank for gross margin in competitive benchmarking in 2022. IDEXX Laboratories had 0.00% gap between actual performance and next performance rank for sales growth in competitive benchmarking in 2022. IDEXX Laboratories had 0 days gap between actual performance and next performance rank for days sales outstanding in competitive benchmarking in 2022. IDEXX Laboratories can reduce overall cost by $$3,813,000,000 by improving both COGS and SGA to next benchmark tier in 2022. IDEXX Laboratories can reduce inventory with practices including SKU Reduction in 2022. IDEXX Laboratories can reduce inventory with practices including Reduce Manufacturing Latency in 2022. IDEXX Laboratories can reduce inventory with practices including Forecast Accuracy in 2022. IDEXX Laboratories can reduce inventory with practices including Demand Shaping in 2022. IDEXX Laboratories can reduce days sales outstanding with practices including in 2022. IDEXX Laboratories can increase sales revenue by $$2,341,000,000 improving sales performance to next benchmark tier in 2022. IDEXX Laboratories can increase revenue growth by $$0 by improving growth performance to next benchmark tier in 2022. IDEXX Laboratories can increase overall revenue by $$2,341,000,000 by improving both growth and sales performance to next benchmark tier in 2022. IDEXX Laboratories can increase days payables outstanding with practices including Strategic Sourcing in 2022. IDEXX Laboratories can increase days payables outstanding by $65,000,000 days by increasing days payables outstanding to next benchmark tier in 2022. IDEXX Laboratories can improve total financial performance by $$6,582,000,000 by improving revenue, costs, and working capital in 2022. IDEXX Laboratories can decrease overall working capital by $$428,000,000 by improving inventory, payables and receivables to next benchmark tier in 2022. IDEXX Laboratories can decrease inventory days by $363,000,000 days by reducing inventory days to next benchmark tier in 2022. IDEXX Laboratories can decrease days sales outstanding by $0 days by reducing days sales outstanding to next benchmark tier in 2022. IDEXX Laboratories can accelerate revenue growth practices including Revenue-optimized Planning in 2022. IDEXX Laboratories can accelerate revenue growth practices including Pricing Optimization in 2022. IDEXX Laboratories can accelerate revenue growth practices including Accelerate Design Pipeline in 2022. 96 days was the measured parity or middle performance level for cash to cash cycle time in IDEXX Laboratories's peer group in 2022. 86 days was the measured parity or middle performance level for days of inventory in IDEXX Laboratories's peer group in 2022. 57 days was the measured advantage or top third performance level for cash to cash cycle time in IDEXX Laboratories's peer group in 2022. 55 days was the measured parity or middle performance level for days sales outstanding in IDEXX Laboratories's peer group in 2022. 50 days was the measured advantage or top third performance level for days sales outstanding in IDEXX Laboratories's peer group in 2022. 46 days was the measured advantage or top third performance level for days of inventory in IDEXX Laboratories's peer group in 2022. 45.64% was the measured parity or middle performance level for cost of goods sold as a percent of revenue in IDEXX Laboratories's peer group in 2022. 43 days was the measured superior or top ten performance level for days sales outstanding in IDEXX Laboratories's peer group in 2022. 41 days was the measured superior or top ten performance level for cash to cash cycle time in IDEXX Laboratories's peer group in 2022. 40.67% was the measured advantage or top third performance level for cost of goods sold as a percent of revenue in IDEXX Laboratories's peer group in 2022. 39.80% was the measured superior or top ten performance level for cost of goods sold as a percent of revenue in IDEXX Laboratories's peer group in 2022. 28.62% was the measured superior or top ten performance level for gross margin in IDEXX Laboratories's peer group in 2022. 13.85% was the measured parity or middle performance level for sales volatility in IDEXX Laboratories's peer group in 2022. 13.30% was the measured advantage or top third performance level for sales volatility in IDEXX Laboratories's peer group in 2022. 11.86% was the measured superior or top ten performance level for sales volatility in IDEXX Laboratories's peer group in 2022. 11 days was the measured superior or top ten performance level for days of inventory in IDEXX Laboratories's peer group in 2022. 0.08% was the measured superior or top ten performance level for sales growth in IDEXX Laboratories's peer group in 2022. -0.04% was the measured parity or middle performance level for sales growth in IDEXX Laboratories's peer group in 2022. -0.00% was the measured advantage or top third performance level for sales growth in IDEXX Laboratories's peer group in 2022. $25.41% was the measured advantage or top third performance level for gross margin in IDEXX Laboratories's peer group in 2022. $19.35% was the measured parity or middle performance level for gross margin in IDEXX Laboratories's peer group in 2022. $$5,708,000,000 was the measured parity or middle performance level for gross revenue in IDEXX Laboratories's peer group in 2022. $$29,812,000,000 was the measured superior or top ten performance level for gross revenue in IDEXX Laboratories's peer group in 2022. $$13,052,000,000 was the measured advantage or top third performance level for gross revenue in IDEXX Laboratories's peer group.